Table 1 Included randomized clinical trials and their baseline characteristics
Author, year | Number of patients randomized | Trial duration (weeks) | Mean age (years) | HbA1c (%) | BMI | Diabetes duration (years) | Add on (Y-Yes N-No) | Control | SU (ref) |
|---|---|---|---|---|---|---|---|---|---|
Seck, 2010 | 1172 | 104 | 57 | 7.3 | 31.2 | 5.8 | Y Metformin 1.5 g | Sitagliptin 100 mg | Glipizide |
5–20 mg [27] | |||||||||
Seino, 2010 | 411 | 24 | 58 | 8.9 | 24.5 | 8.3 | N | Liraglutide 0.9 mg | Glibenclamide 2.5 mg [28] |
Arechavaleta, 2011 | 1035 | 30 | 56 | 7.4 | 30 | 6.8 | Y Metformin 1.5 g | Sitagliptin 100 mg | Glimepiride |
1–6 mg [29] | |||||||||
Filozof, 2010 | 1007 | 52 | 60 | 8.5 | 31 | 6.6 | Y Metformin 1.5 g | Vildagliptin 50 mg twice daily | Gliclazide |
80–320 mg [30] | |||||||||
Foley, 2009 | 1092 | 104 | 55 | 8.6 | 30.7 | 2.2 | N | Vildagliptin 50 mg twice daily | Gliclazide |
80–320 mg | |||||||||
[31] | |||||||||
Garber, 2009 | 746 | 52 | 53 | 8.3 | 33.1 | 5.4 | N | Liraglutide 1.2 mg Liraglutide 1.8 mg | Glimepiride |
8 mg [32] | |||||||||
Kahn, 2006 | 2902 | 208 | 57 | 7.4 | 32.2 | 3.7 | N | Metformin | Glyburide |
(median) | 2 g | 7.5 mg twice daily [26] | |||||||
Ferrannini, 2009 | 2789 | 52 | 57 | 7.3 | 31.7 | 5.7 | Y Metformin 1.9 g | Vildagliptin 50 mg twice daily | Glimepiride |
2–6 mg [33] | |||||||||
Yki-Järvinen, 1999 | 48 | 52 | 59 | 9.8 | 29.3 | NR | Y | Metformin | Glyburide 10.5 mg [34] |
NPH insulin | 2 g | ||||||||
Nomoto, 2016 | 103 | 26 | 61 | 7.4 | 25.5 | NR | Y | Sitagliptin 100 mg | Glimepiride 0.5-2 mg/day |
55% Metformin | [35] | ||||||||
Dose NR | |||||||||
Derosa, 2013 | 453 | 52 | NR | 8.3 | 27.5 | 5 | Y Metformin 2.2 g Pioglitazone 30 mg | Sitagliptin 100 mg | Glibenclamide 5 mg 3 times a day [36] |
Rosenstock, 2013 | 441 | 52 | 70 | 7.5 | 29.8 | 6.1 | No | Alogliptin | Glipizide |
25 mg | 5–10 mg [37] | ||||||||
Leiter, 2015 | 1452 | 104 | 56 | 7.8 | 31 | 6.6 | Y Metformin > 1.5 g | Canagliflozin 100 mg or 300 mg | Glimepiride |
1–8 mg [38] | |||||||||
Erem, 2014 | 40 | 52 | 53 | 7.9 | 32.5 | NR | N | Metformin | Gliclazide |
2 g Pioglitazone 45 mg | 30–120 mg [39] | ||||||||
Ridderstråle, 2014 | 1549 | 104 | 56 | 7.9 | 30.2 | NR | Y | Empagliflozin 25 mg | Glimepiride 1–4 mg [40] |
Metformin > 1.5 g | |||||||||
Nauck, 2014 | 816 | 104 | 58 | 7.7 | 31.5 | 6.5 | Y, Metformin ≥ 1.5 g | Dapagliflozin 2.5–10 mg | Glipizide |
5–20 mg [41] | |||||||||
Del Prato, 2014 | 2639 | 104 | 55 | 7.6 | 31.2 | 5.5 | Y Metformin ≥ 1.5 g or | Alogliptin 12.5 or 25 mg | Glipizide |
5–20 mg [42] | |||||||||
Gudipaty, 2014 | 47 | 24 | 55 | 6.5 | 32.3 | 4 | N | Sitagliptin 100 mg | Glimepiride 0.5-4 mg [43] |
Hong, 2013 | 304 | 156 | 63 | 7.6 | 25.2 | 5.6 | N | Metformin 0.75–1.5 g | Glipizide |
15–30 mg [7] | |||||||||
Pérez, 2015 | 400 | 24 | 49 | 9.6 | 24.5 | NR | N | Sitagliptin 100 mg | Glimepiride |
2–6 mg [44] | |||||||||
Ferreira, 2013 (1) | 129 | 54 | 60 | 7.9 | 26.8 | 17.5 | N | Sitagliptin | Glipizide |
25 mg | 2.5–20 mg [45] | ||||||||
Ferreira, 2013 (2) | 426 | 54 | 64 | 7.8 | 26.8 | 10.4 | N | Sitagliptin | Glipizide |
25 or 50 mg | 2.5–20 mg [46] | ||||||||
Schernthaner, 2015 | 720 | 52 | 73 | 7.6 | 29.6 | 7.6 | Y Metformin 1.6 g (mean) | Saxagliptin | Glimepiride |
5 mg | 1–6 mg [47] | ||||||||
Hartley, 2015 | 480 | 32 | 71 | 7.8 | 29.7 | 8.7 | N | Sitagliptin | Glimepiride |
50 or 100 mg | 1–6 mg [48] | ||||||||
Gallwitz, 2012 | 1029 | 208 | 56 | 7.5 | 32.5 | 5.7 | Y Metformin 2 g (median) | Exenatide | Glimepiride |
10–20 µg | 1 mg [49] | ||||||||
Ahrén, 2014 | 945 | 104 | 55 | 8.1 | 32.6 | 6.1 | Y Metformin ≥ 1.5 g or MTD | Albiglutide 30–50 mg, Sitagliptin 100 mg | Glimepiride |
2–4 mg [50] | |||||||||
Barnett, 2012 | 227 | 52 | 57 | 8.1 | 29.7 | NR | N | Linagliptin | Glimepiride |
5 mg | 1–4 mg [51] | ||||||||
Nauck, 2013 | 1091 | 104 | 57 | 8.4 | 31.1 | 7.6 | Y Metformin 2 g | Liraglutide 0.6, 1.2 or 1.8 mg | Glimepiride |
4 mg [52] | |||||||||
Del Prato, 2015 | 814 | 208 | 58 | 7.7 | 31.5 | 6.4 | Y Metformin 1.5–2.5 g | Dapagliflozin 2.5, 5 or 10 mg | Glipizide |
5–20 mg [53] | |||||||||
Göke, 2013 | 858 | 104 | 58 | 7.7 | 31.4 | 5.5 | Y Metformin ≥ 1.5 g | Saxagliptin | Glipizide |
5 mg | 5–20 mg [54] | ||||||||
Berndt-Zipfel, 2013 | 44 | 24 | 59 | 7.4 | 33.9 | 73 | Y | Vildagliptin 100 mg | Glimepiride 0.5-4 mg [55] |
Metformin | |||||||||
Dose NR |